Effect of N-acetylcysteine on inflammatory markers in hemodialysis patients

Evaluation of effect of N-acetylcysteine on inflammatory markers in hemodialysis patients who referred to Shahid Beheshti hospital, Yasuj, Iran in 2015

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015062222869N1

Enrollment

Registered

2015-10-22

Start date

2015-09-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage renal disease. End stage kidney disease

Interventions

Intervention 1: Intervention group: N-acetylcysteine tab, 600 mg bid for 2 month period. Intervention 2: control group: placebo tab bid, for 2 month period.

Treatment - Drugs

Intervention group: N-acetylcysteine tab, 600 mg bid for 2 month period

control group: placebo tab bid, for 2 month period

Eligibility

Sex/Gender

All

Age

24 Years to 88 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients aged > 18 years; patients who were dialysed at least two times per week for a 3 month period Exclusion criteria:patients who take anti-inflammatory drugs such as steroids; patients who have active infectious disease, malignancy, kidney transplantation, rheumatic diseases

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Interleukin-6. Timepoint: 2 month. Method of measurement: ELIZA.;CRP. Timepoint: 2 month. Method of measurement: ELIZA.	—

Secondary

Measure	Time frame
Drug reaction. Timepoint: 2 month. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMoslem Sedaghattalb

Yasuj University of Medical Science

m.sedaghattalab@yums.ac.ir; moslem.sedaghattalab@gmail.com+98 74 3322 0163

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026